Catecholamine-mediated release of miR-133a-3p from adipocytes regulates the onset of chronic primary pain.

Summary

The study identifies adipocyte-derived miR-133a-3p as a cross-species biomarker and regulator of chronic primary pain: its plasma levels are reduced in humans and rodent models, it traffics via extracellular vesicles to the spinal cord, and adipose-specific overexpression reverses mechanical hypersensitivity. Mechanistically, catecholamine signaling downregulates miR-133a-3p in white adipocytes, disinhibiting spinal pain genes such as MAP3K3.

Key Findings

• Plasma miR-133a-3p is consistently downregulated in humans with ≥1 chronic primary pain condition and in rodent primary pain models.
• miR-133a-3p is released by white adipocytes in extracellular vesicles and traffics to the spinal cord.
• Catecholamine (adrenergic) activation downregulates adipocyte miR-133a-3p, disinhibiting spinal pain genes including MAP3K3.
• Adipose-specific overexpression of miR-133a-3p reverses mechanical hypersensitivity in both male and female mice.

Clinical Implications

miR-133a-3p may serve as a blood biomarker for chronic primary pain and a therapeutic target (e.g., adipose-targeted miR mimics/EV delivery). Translation will require safety, delivery, and durability studies.

Limitations

• Human cohort sizes and demographics are not detailed in the abstract, limiting immediate generalizability.
• Extracellular vesicle origin and biodistribution mechanisms, while suggested, require formal in vivo tracking and safety profiling for translation.

Future Directions

Develop and test adipose-targeted miR-133a-3p delivery systems, validate biomarker performance in diverse CPPC cohorts, and assess long-term efficacy/safety in large animals.